HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Numico Consolidation Of Rexall, GNC Operations To Save $36 Mil.

This article was originally published in The Tan Sheet

Executive Summary

Royal Numico expects to save $36 mil. after eliminating overlapping operations and inefficiencies from its Rexall Sundown and General Nutrition businesses.

You may also be interested in...



Numico Supplement Sales Up Over 1300% Due To GNC, Rexall Acquisitions

General Nutrition Companies' U.S. same-store sales increased 9.3% in the first half of 2000, according to data recently made available by parent company Royal Numico. Same-store sales for GNC outlets overseas rose 13.2% compared to the first half of 1999, Numico reported.

Weider's Schiff Move Free FY 2000 Sales Jump 55% To $110 Mil.

Schiff Move Free glucosamine/chondroitin sales spiked 55% to approximately $110 mil. for the fiscal year ended May 31, Weider President and CEO Bruce Wood told analysts during a conference call Aug. 18.

Royal Numico/Rexall Sundown Eyes Private Label As Key Growth Area

Combined Royal Numico/Rexall Sundown operations regard their potential for private label sales in the U.S. mass market to be "very high," the firms reported during a May 1 teleconference. Numico and Rexall have little presence in U.S. private label now but appear to be pondering it for the future despite the traditional low margins of the products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS132943

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel